Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

4104 - Lung cancer predisposition in women with previous breast cancer identified by whole exome sequencing

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Presenters

Francesco Grossi

Citation

Annals of Oncology (2018) 29 (suppl_8): viii670-viii682. 10.1093/annonc/mdy304

Authors

F. Grossi1, C. Genova1, D. Cittaro2, S. Bonfiglio2, S. Boccardo1, I. Vanni1, M. Mora3, M.G. Dal Bello1, F. Biello1, E. Rijavec1, C. Sini1, G. Rossi1, M. Tagliamento1, A. Alama1, G. Burrafato1, G. Barletta1, A. Ballestrero4, S. Coco1

Author affiliations

  • 1 Lung Cancer Unit, Ospedale Policlinico San Martino, 16132 - Genoa/IT
  • 2 Centre For Translational Genomics And Bioinformatics, IRCCS San Raffaele Scientific Institute,, Milan/IT
  • 3 Pathology Unit, Ospedale Policlinico San Martino, Genoa/IT
  • 4 Department Of Internal Medicine, University of Genoa, Genoa/IT
More

Resources

Abstract 4104

Background

Women treated for breast cancer (BC) are at risk to develop a subsequent lung cancer (LC; relative risk ranging from 1.38 to 5.05), especially in case of smoking history and if adjuvant radiation (aRT) was administered for BC. We hypothesized that genetic variants might predispose patients (Pts) to develop LC after BC. Our aim was to perform whole exome sequencing (WES) to identify genes associated with such predisposition.

Methods

28 women with diagnosis of LC after BC (Study Population, SP) were enrolled, as well as 32 women treated for BC and with no secondary cancer after a follow-up ≥10 years (control population; CP). DNA was extracted from tumors and normal tissue samples from both SP and CP. Libraries were prepared with Agilent SureSelect All Exon kit and sequenced on Illumina HiSeq2500. Variant calling was performed with FreeBayes software.

Results

The median age of SP at BC diagnosis was 63.5 years (range: 47-76); the median interval between diagnosis of BC and occurrence of LC was 4.5 years (range: 0-11). 13 Pts (46%) were never-smokers and, among the 21 Pts who had received aRT, 13 (62%) developed ipsilateral LC. At somatic analysis, no common mutation among known driver genes was shared between each BC and LC pair in SP Pts. WES performed on BC and LC samples identified two mutational signatures (S1 and S2). S1 (C>T substitutions) was observed in all BC samples and 16/28 (57%) LC samples and was more frequent in never-smokers (11 vs. 5 Pts) and among Pts who developed ipsilateral LC after aRT (10 vs. 6 Pts). S2 (C>A transversions) was observed in 12/28 LC samples (43%) and was strongly associated with smoking habit (10 vs. 2 Pts). When compared with COSMIC libraries, S2 results were similar to COSMIC 4, common in LC samples collected from smokers. Since S1 was largely shared between paired BC and LC samples, we explored the eventuality of a genetic predisposition to S1-related malignancies with a gene-based burden test over rare germline variants in normal tissue of S1-LC Pts compared with CP Pts; 249 candidate genes were identified (FDR<0.05).

Conclusions

Our data identified two mutational signatures underlying the LC development. Germline analysis suggests that genetic variants may contribute to increase the risk of LC after BC.

Clinical trial identification

Legal entity responsible for the study

Ospedale Policlinico San Martino.

Funding

Italian Ministry of Health (GR-2011-02350922).

Editorial Acknowledgement

Disclosure

F. Grossi: Honoraria: BMS, MSD, AstraZeneca, Pierre Fabre, Boehringer Ingelheim, Pfizer, Celgene, Amgen, Roche. C. Genova: Honoraria: AstraZeneca, Boehringer Ingelheim, BMS, MSD, Roche. G. Barletta: Employee: AstraZeneca. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings